Defines testing, performance, and disclosure requirements for devices that use advanced algorithms to help detect gastrointestinal lesions.
Requires devices that used advanced algorithms to help detect gastrointestinal lesions ("gastrointestinal lesion software detection systems") to undergo specified clinical and non-clinical performance tests and to demonstrate reliability and safety.
Requires gastrointestinal lesion software detection systems to be labeled with use instructions, warnings, and summaries of testing.
Key facts
🏛️ This document has been enacted by the U.S. Food and Drug Administration.
For authoritative text and metadata, visit the official source.
🎯 This document primarily applies to the private sector, rather than the government.
📜 This document's name is 21 CFR § 876.1520 ("Gastrointestinal lesion software detection system").
Themes
AI risks, applications, governance strategies, and other themes addressed in AGORA documents.
This tag applies to documents that address whether humans can understand (a) the mechanisms underlying an AI system’s operation and/or (b) the meaning of the systems’ output in the context of use.
This tag applies to documents that address the ability of an AI system to perform as required, without failure, under the conditions of expected use and over a given period of time, including the entire lifetime of the system.
This tag applies to documents that govern whether, how, and/or to what extent people who are affected by or otherwise have an interest in an AI system have access to relevant information about the system.
This tag applies to documents that require, encourage, etc. the disclosure of information about AI systems by their users, developers, vendors, or others directly involved with the systems to third parties, including but not limited to the general public.
This tag applies to documents that require, encourage, etc. the systematic evaluation of AI systems, or of broader systems or processes into which AI is directly integrated.
This tag applies to documents that discuss evaluations that assess whether deployed AI systems meet the expectations specified or claimed prior to deployment.
This tag applies to documents that require or incentivize AI systems to incorporate specific features or achieve (or not achieve) specified results in operation, or to be used or not to be used in specified ways or for specific purposes. Requirements may be defined objectively (e.g., systems must score above a certain level on an established benchmark, systems must incorporate a certain technical feature) or subjectively (e.g., systems must not demonstrate undue bias).
This is an unofficial copy. The document has been
archived and reformatted in plaintext for AGORA. Footnotes, tables, and
similar material may be omitted. For the official text, visit the original source.
PART 876—GASTROENTEROLOGY-UROLOGY DEVICES
1. The authority citation for part 876 continues to read as follows:
Authority:
21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
1. Add § 876.1520 to subpart B to read as follows:
§ 876.1520
Gastrointestinal lesion software detection system.
(a)
Identification.
A gastrointestinal lesion software detection system is a computer-assisted detection device used in conjunction with endoscopy for the detection of abnormal lesions in the gastrointestinal tract. This device with advanced software algorithms brings attention to images to aid in the detection of lesions. The device may contain hardware to support interfacing with an endoscope.
Adds a gastrointestinal lesion software detection system for assisting endoscopy in detecting gastrointestinal tract abnormalities.
Adds a gastrointestinal lesion software detection system for assisting endoscopy in detecting gastrointestinal tract abnormalities.
(b)
Classification.
Class II (special controls). The special controls for this device are:
(1) Clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use, including detection of gastrointestinal lesions and evaluation of all adverse events.
(2) Non-clinical performance testing must demonstrate that the device performs as intended under anticipated conditions of use. Testing must include:
(i) Standalone algorithm performance testing;
(ii) Pixel-level comparison of degradation of image quality due to the device;
(iii) Assessment of video delay due to marker annotation; and
(iv) Assessment of real-time endoscopic video delay due to the device.
Classifies the device as Class II with required clinical and non-clinical performance testing under specified conditions.
Classifies the device as Class II with required clinical and non-clinical performance testing under specified conditions.
(3) Usability assessment must demonstrate that the intended user(s) can safely and correctly use the device.
(4) Performance data must demonstrate electromagnetic compatibility and electrical safety, mechanical safety, and thermal safety testing for any hardware components of the device.
Requires usability assessment to ensure safe, correct device use by intended users. Requires performance data to demonstrate device safety.
Requires usability assessment to ensure safe, correct device use by intended users. Requires performance data to demonstrate device safety.
(5) Software verification, validation, and hazard analysis must be provided. Software description must include a detailed, technical description including the impact of any software and hardware on the device's functions, the associated capabilities and limitations of each part, the associated inputs and outputs, mapping of the software architecture, and a description of the video signal pipeline.
Requires providing software verification, validation, hazard analysis, and a detailed technical description of software functions.
Requires providing software verification, validation, hazard analysis, and a detailed technical description of software functions.
(6) Labeling must include:
(i) Instructions for use, including a detailed description of the device and compatibility information;
(ii) Warnings to avoid overreliance on the device, that the device is not intended to be used for diagnosis or characterization of lesions, and that the device does not replace clinical decision making;
(iii) A summary of the clinical performance testing conducted with the device, including detailed definitions of the study endpoints and statistical confidence intervals; and
(iv) A summary of the standalone performance testing and associated statistical analysis.
Dated: December 27, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
Mandates labeling to include instructions, warnings, and summaries of clinical and standalone performance testing.
Mandates labeling to include instructions, warnings, and summaries of clinical and standalone performance testing.